| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1499 | 2016 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 858 | 2017 |
| Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort … JL McQuade, CR Daniel, KR Hess, C Mak, DY Wang, RR Rai, JJ Park, ... The Lancet Oncology 19 (3), 310-322, 2018 | 614 | 2018 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 583 | 2021 |
| Systematic review of acupuncture in cancer care: a synthesis of the evidence MK Garcia, J McQuade, R Haddad, S Patel, R Lee, P Yang, JL Palmer, ... Journal of Clinical Oncology 31 (7), 952-960, 2013 | 387 | 2013 |
| Modulating the microbiome to improve therapeutic response in cancer JL McQuade, CR Daniel, BA Helmink, JA Wargo The Lancet Oncology 20 (2), e77-e91, 2019 | 354 | 2019 |
| Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations CH Kugel III, SM Douglass, MR Webster, A Kaur, Q Liu, X Yin, SA Weiss, ... Clinical Cancer Research 24 (21), 5347-5356, 2018 | 345 | 2018 |
| Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade MC Andrews, CPM Duong, V Gopalakrishnan, V Iebba, WS Chen, ... Nature medicine 27 (8), 1432-1441, 2021 | 319 | 2021 |
| Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised … RN Amaria, PA Prieto, MT Tetzlaff, A Reuben, MC Andrews, MI Ross, ... The lancet oncology 19 (2), 181-193, 2018 | 305 | 2018 |
| Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases GM Fischer, A Jalali, DA Kircher, WC Lee, JL McQuade, LE Haydu, ... Cancer discovery 9 (5), 628-645, 2019 | 302 | 2019 |
| Systemic therapy for melanoma: ASCO guideline R Seth, H Messersmith, V Kaur, JM Kirkwood, R Kudchadkar, ... Journal of Clinical Oncology 38 (33), 3947-3970, 2020 | 289 | 2020 |
| Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202–216. doi: 10.1158/2159-8290 W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... CD-15-0283, 2018 | 271 | 2018 |
| Neoadjuvant relatlimab and nivolumab in resectable melanoma RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross, C Torres-Cabala, ... Nature 611 (7934), 155-160, 2022 | 245 | 2022 |
| Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium RN Amaria, AM Menzies, EM Burton, RA Scolyer, MT Tetzlaff, ... The Lancet Oncology 20 (7), e378-e389, 2019 | 226 | 2019 |
| Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial Z Chen, Z Meng, K Milbury, W Bei, Y Zhang, B Thornton, Z Liao, Q Wei, ... Cancer 119 (9), 1690-1698, 2013 | 194 | 2013 |
| Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications GM Fischer, YN Vashisht Gopal, JL McQuade, W Peng, RJ DeBerardinis, ... Pigment cell & melanoma research 31 (1), 11-30, 2018 | 180 | 2018 |
| Genome-wide variation of cytosine modifications between European and African populations and the implications for complex traits EL Moen, X Zhang, W Mu, SM Delaney, C Wing, J McQuade, J Myers, ... Genetics 194 (4), 987-996, 2013 | 144 | 2013 |
| Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy E Shiuan, KE Beckermann, A Ozgun, C Kelly, M McKean, J McQuade, ... Journal for immunotherapy of cancer 5, 1-6, 2017 | 143 | 2017 |
| Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection M Tio, R Rai, OM Ezeoke, JL McQuade, L Zimmer, C Khoo, JJ Park, ... European Journal of Cancer 104, 137-144, 2018 | 126 | 2018 |
| Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma CN Owen, X Bai, T Quah, SN Lo, C Allayous, S Callaghan, ... Annals of Oncology 32 (7), 917-925, 2021 | 125 | 2021 |
